Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BJDX - Bluejay Diagnostics, Inc.
Market Cap 5.59M P/E - EPS this Y - Ern Qtrly Grth -
Income -9.4M Forward P/E -1.18 EPS next Y - 50D Avg Chg 8.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -42.00%
Dividend N/A Price/Book 0.61 EPS next 5Y - 52W High Chg -78.00%
Recommedations - Quick Ratio 3.92 Shares Outstanding 552.85K 52W Low Chg 44.00%
Insider Own 1.15% ROA -58.51% Shares Float 6.24M Beta 0.73
Inst Own 0.95% ROE -125.25% Shares Shorted/Prior 159.89K/97.68K Price 5.46
Gross Margin - Profit Margin - Avg. Volume 405,831 Target Price -
Oper. Margin - Earnings Date - Volume 263,305 Change -5.04%
Healthcare | Medical Devices | United States
About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Bluejay Diagnostics, Inc. News
11/13/24 Bluejay Diagnostics Announces Reverse Stock Split
06/28/24 Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
06/27/24 Top Midday Decliners
06/27/24 Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering
06/26/24 SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
05/24/24 BJDX: 1Q:24 Financial Update
04/09/24 BJDX: 2023 Financial Update
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fisher Kenneth R Chief Financial Offi.. Chief Financial Officer Aug 26 Buy 1.0300 20,000 20,600 40,000 09/07/22
Kinder Gordon Winston Chief Financial Offi.. Chief Financial Officer Mar 17 Buy 1.159 2,500 2,898 18,500 03/21/22
Dey Svetlana Director Director Mar 17 Buy 1.183 10,000 11,830 10,000 03/21/22
Wurth Douglas Clark Director Director Mar 17 Buy 1.178 40,000 47,120 2,286,349 03/18/22
Wurth Douglas Clark Director Director Mar 16 Buy 1.09 60,000 65,400 2,246,349 03/17/22
Kinder Gordon Winston Chief Financial Offi.. Chief Financial Officer Mar 14 Buy 0.96 16,000 15,360 16,000 03/16/22